Swiss Re has appointed Damien Bartlett as head of market unit Life & Health UK and Ireland and Middle East and Africa, and Karen Tan as chief underwriting officer for L&H Re. The moves follow last week's announcement of Velina Peneva as incoming L&H Re CEO, and together represent a broad reset of the unit's senior leadership structure.
Bartlett takes up his position on November 1, filling the vacancy created when Tamas Bown moved earlier this year to lead Swiss Re's L&H business across Asia Pacific ex China.
Bartlett joins from SCOR, where he started his career in 2001 and most recently served as global head of in-force management, head of strategy and COO for Life & Health. He previously served as regional CEO for EMEA and Canada at SCOR and led the firm's UK, Ireland, South Africa, Canada and Australia markets.
Tan assumes her new role on October 1, the same date Peneva steps in as CEO of L&H Re. Peneva succeeds Paul Murray, who decided to leave Swiss Re after more than 20 years.
Tan is an internal promotion from her current role as chief risk officer of L&H Re. Her prior roles at Swiss Re include head of Life & Health Products Asia and chief risk officer for Asia Pacific.
The appointments arrive as L&H Re has become a more prominent contributor to Swiss Re's group results. The unit posted net income of US$1.045 billion for the first half of 2026, a 21% increase year on year, driven by favourable US mortality experience and healthy in-force margins. As P&C Re pricing faces downward pressure, L&H Re's insurance service result reached US$1.158 billion, up 24%, providing earnings diversification across the group.
Swiss Re Group CEO Andreas Berger described L&H Re as providing "important earnings stability through its large in-force portfolio." The unit carries a full-year net income target of US$1.7 billion for 2026, set after Swiss Re materially completed a review of underperforming portfolios in Australia, Israel, and South Korea in 2025. That review carried an estimated US$250 million IFRS pre-tax earnings impact.
Swiss Re group chief financial officer Anders Malmström said the H1 result reflected healthy underwriting margins and favourable US mortality experience in L&H Re. P&C underwriting was also strong.
P&C Re recorded a nominal price decrease of 1.2% at the mid-year renewals. On a risk-adjusted basis, that figure widens to 5.3%, pointing to L&H Re's growing earnings role across the group.
For reinsurance brokers placing life and health treaty business, both appointments are worth reading against the backdrop of that 2025 portfolio review specifically. Bartlett's remit covers UK and Ireland alongside Middle East and Africa, a combination that puts newly consolidated leadership over a broader geographic footprint than the region has had under one executive recently. Cedants and brokers in those markets should treat his arrival as an opportunity to confirm current underwriting appetite directly, particularly for treaty structures in regions where Swiss Re has been actively repricing or restructuring underperforming business elsewhere in its book.
Tan's move from chief risk officer to chief underwriting officer is the more structurally significant of the two for underwriting standards specifically. A CUO arriving with a CRO's background, rather than a traditional underwriting career path, is a reasonable signal that risk discipline and underwriting decisions will be more tightly integrated under her tenure than under a conventional split between the two functions. For brokers negotiating treaty terms with L&H Re, that may translate into more rigorous risk-selection standards at the point of underwriting, rather than risk appetite being adjusted separately after the fact through a distinct risk function. Given L&H Re's stated 2026 net income target and its growing importance to group earnings, cedants with maturing treaties should factor in that this leadership team has a clear incentive to protect underwriting margins as pricing softens elsewhere in the group's P&C book.
